纳米病毒的抗病毒药物NV-387在刚果进入了对天花的第二阶段试验,在印度对呼吸道病毒进行了适应性试验,美国也有可能进行试验。 NanoViricides' antiviral drug NV-387 enters Phase 2 trials for mpox in Congo and an adaptive trial in India for respiratory viruses, with U.S. trials possible.

纳米病毒公司正在两个临床轨道上推进其广谱抗病毒药物NV-387:预计于2025年底或2026年初在刚果开始的对天花的第二阶段试验,以及在印度针对流感、RSV和冠状病毒等呼吸道病毒进行的适应性试验,可能从2026年冬季开始。 NanoViricides, Inc. is advancing its broad-spectrum antiviral drug NV-387 in two clinical tracks: a Phase 2 trial for mpox expected to start in late 2025 or early 2026 in Congo, and an adaptive trial in India targeting respiratory viruses like influenza, RSV, and coronaviruses, possibly beginning in winter 2026. 该药物使用纳米聚合小鼠摧毁血液中的病毒,在2023年第一阶段试验中显示出安全性。 The drug, which uses nano-polymer micelles to destroy viruses in the blood, showed safety in a 2023 Phase 1 trial. 美国可能从BARDA和美国今后的审判获得资金。 Potential U.S. funding from BARDA and future trials in the U.S. may follow. 该公司还探索NV-387,用于长期COVID、shingles和其他病毒条件,还有更多候选人正在开发中。 The company also explores NV-387 for long COVID, shingles, and other viral conditions, with additional candidates in development.